NRx Pharmaceuticals and HOPE Therapeutics to Showcase Developments at Neuro Perspectives Conference
TL;DR
NRx Pharmaceuticals' participation in the H.C. Wainwright conference offers investors a unique opportunity to gain insights into its NMDA platform and NRX-101's potential market advantages.
NRx Pharmaceuticals will present at the H.C. Wainwright conference, detailing its NMDA platform's role in developing treatments for CNS disorders and its NDA filing process for NRX-101.
NRx Pharmaceuticals' work on NRX-101 and NRX-100 could significantly improve treatment options for suicidal depression and chronic pain, enhancing patient care and quality of life.
Discover how NRx Pharmaceuticals is pioneering NMDA-based therapies for CNS disorders, with NRX-101 poised to revolutionize treatment for suicidal depression and chronic pain.
Found this article helpful?
Share it with your network and spread the knowledge!
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and its wholly owned subsidiary HOPE Therapeutics, Inc. have announced their participation in the upcoming H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. Scheduled for June 16–17, 2025, the event will feature a corporate presentation by Dr. Jonathan Javitt, Founder, Chairman, and CEO of NRx and Co-CEO of HOPE, detailing recent developments in their research and treatment offerings. This presentation will be available on demand to registered attendees starting at 7 a.m. ET on June 16, alongside one-on-one investor meetings.
The significance of this participation lies in the potential impact of NRx Pharmaceuticals' work on treating central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD. With NRX-101, an FDA-designated investigational Breakthrough Therapy, and NRX-100 (IV ketamine) for suicidal depression, the company is at the forefront of developing non-opioid treatments for chronic pain and innovative solutions for mental health crises. The upcoming conference provides a platform to share these advancements with investors and the broader medical community, underscoring the importance of continued investment and research in this critical area of healthcare.
Curated from InvestorBrandNetwork (IBN)
